Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 12/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | SIK1 | P57059 | 1/20 | 0.44 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456912 | 0.93 | PDPK1 (0.68) | PDPK1PIK3CAPIK3CDTNIKPAK1 | |
| SCHEMBL1456803 | 0.91 | PDPK1 (0.80) | PDPK1PIK3CAPIK3CDPAK1PAK4 | |
| SCHEMBL1456037 | 0.89 | PDPK1 (0.83) | PDPK1PIK3CAPIK3CDTNIKPIK3CG | |
| SCHEMBL2424135 | 0.88 | PDPK1 (0.69) | PDPK1PIK3CAPIK3CDTNIKPAK1 | |
| SCHEMBL1456941 | 0.86 | PDPK1 (0.77) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1456765 | 0.84 | PDPK1 (0.81) | PDPK1PIK3CAPIK3CDPAK1PAK4 | |
| SCHEMBL1457186 | 0.82 | PDPK1 (0.84) | PDPK1PIK3CAPIK3CDTNIKPIK3CG | |
| SCHEMBL27922675 | 0.81 | PDPK1 (0.54) | PDPK1PIK3CAPIK3CDPAK1PAK4 | |
| SCHEMBL2420578 | 0.81 | PDPK1 (0.70) | PDPK1PIK3CAPIK3CDTNIKPAK1 | |
| SCHEMBL27922673 | 0.81 | PDPK1 (0.53) | PDPK1PIK3CAPIK3CDPAK1PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291375-B1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-06 | — | — | EP | claimed |
| JP-2011526260-A | — | — | 2011-10-06 | — | — | JP | claimed |
| EP-2291375-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | claimed |
| WO-2010000364-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-01-07 | — | — | WO | claimed |
| EP-2291375-B1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2291375-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| WO-2010000364-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MKI67, CCNT1, CCNI | PDPK1 429/4885PIK3CA 2075/4885PIK3CD 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.